(S)-2-(5-benzyl-[1,3,4]oxadiazol-2-yl)-piperidine

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: (S)-2-(5-benzyl-[1,3,4]oxadiazol-2-yl)-piperidine
• 英文别名: 2-benzyl-5-[(2S)-piperidin-2-yl]-1,3,4-oxadiazole
• 化学式: C₁₄H₁₇N₃O
• 分子量: 243.308
• InChiKey: SVURLEMKGUBFHL-LBPRGKRZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  51
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (S)-2-(5-benzyl-[1,3,4]oxadiazol-2-yl)-piperidine 、 1-(3,4,5-Trimethoxy-phenylsulfamoyl)-piperidine-2S-carboxylic acid 4-phenyl-butyl ester 、 二甲胺基磺酰氯 以45%的产率得到2S-(5-Benzyl-[1,3,4]oxadiazol-2-yl)-piperidine-1-sulfonic acid dimethylamide
  参考文献：
  名称：

  Compounds, compositions, and methods for stimulating neuronal growth and elongation

  摘要：

  本发明涉及用于刺激神经元细胞中神经元生长的方法、药物化合物和组合物，从而导致神经再生。这些方法、化合物和组合物抑制了与结合蛋白相关的旋转酶酶活性。

  公开号：

  US20020061881A1

文献信息

• Novel agents for preventing and treating disorders involving modulation of the RyR receptors
  申请人：Marks R. Andrew

  公开号：US20070049572A1

  公开（公告）日：2007-03-01

  The present invention provides novel compounds of Formula I and salts, hydrates, solvates, complexes, and prodrugs thereof. The present invention further provides methods for synthesizing compounds of Formula I. The invention additionally provides pharmaceutical compositions comprising the compounds of Formula I and methods of using the pharmaceutical compositions of Formula I to treat and prevent disorders and diseases associated with the RyR receptors that regulate calcium channel functioning in cells. Such disorders and diseases include, by way of example only, cardiac disorders and diseases, skeletal muscular disorders and diseases, cognitive disorders and diseases, malignant hyperthermia, diabetes, and sudden infant death syndrome. Cardiac disorder and diseases include, but are not limited to, irregular heartbeat disorders and diseases; exercise-induced irregular heartbeat disorders and diseases; sudden cardiac death; exercise-induced sudden cardiac death; congestive heart failure; chronic obstructive pulmonary disease; and high blood pressure. Irregular heartbeat disorders and diseases include and exercise-induced irregular heartbeat disorders and diseases include, but are not limited to, atrial and ventricular arrhythmia; atrial and ventricular fibrillation; atrial and ventricular tachyarrhythmia; atrial and ventricular tachycardia; catecholaminergic polymorphic ventricular tachycardia (CPVT); and exercise-induced variants thereof. Skeletal muscular disorder and diseases include, but are not limited to, skeletal muscle fatigue, exercise-induced skeletal muscle fatigue, muscular dystrophy, bladder disorders, and incontinence. Cognitive disorders and diseases include, but are not limited to, Alzheimer's Disease, forms of memory loss, and age-dependent memory loss.

  本发明提供了Formula I的新化合物及其盐、水合物、溶剂合物、络合物和前药。本发明还提供了合成Formula I化合物的方法。此外，该发明还提供了包含Formula I化合物的药物组合物，以及使用Formula I药物组合物治疗和预防与调节细胞中钙通道功能的RyR受体相关的疾病和疾病的方法。这些疾病包括但不限于心脏疾病、骨骼肌肉疾病、认知障碍和疾病、恶性高热、糖尿病和婴儿猝死综合征。心脏疾病包括但不限于心律不齐疾病、运动诱发的心律不齐疾病、猝死、运动诱发的猝死、充血性心力衰竭、慢性阻塞性肺疾病和高血压。心律不齐疾病和疾病包括运动诱发的心律不齐疾病，但不限于心房和心室心律失常、心房和心室颤动、心房和心室快速心律失常、心房和心室快速心跳、儿茶酚胺多形性心室心动过速（CPVT）及其运动诱发的变体。骨骼肌肉疾病包括但不限于骨骼肌疲劳、运动诱发的骨骼肌疲劳、肌肉萎缩、膀胱疾病和失禁。认知障碍和疾病包括但不限于阿尔茨海默病、各种记忆丧失形式和年龄相关的记忆丧失。
• Agents for preventing and treating disorders involving modulation of the ryr receptors
  申请人：The Trustees of Columbia University in the City of New York

  公开号：EP2311464A1

  公开（公告）日：2011-04-20

  The present invention provides compounds of Formula I, (I) and salts, hydrates, solvates, complexes, and prodrugs thereof. The present invention further provides methods for synthesizing compounds of Formula I. The invention additionally provides pharmaceutical compositions comprising the compounds of Formula I and methods of using the pharmaceutical compositions of Formula I to treat and prevent disorders and diseases associated with the RyR receptors that regulate calcium channel functioning in cells.

  本发明提供了式I、(I)化合物及其盐类、水合物、溶质、络合物和原药。本发明进一步提供了合成式 I 化合物的方法。本发明还提供了包含式I化合物的药物组合物，以及使用式I药物组合物治疗和预防与调节细胞中钙离子通道功能的RyR受体有关的紊乱和疾病的方法。
• COMPOUNDS, COMPOSITIONS, AND METHODS FOR STIMULATING NEURONAL GROWTH AND ELONGATION
  申请人：AGOURON PHARMACEUTICALS, INC.

  公开号：EP1237869A1

  公开（公告）日：2002-09-11
• Agents for preventing and treating disorders involving modulation of the RyR receptors
  申请人：Marks R. Andrew

  公开号：US20070173482A1

  公开（公告）日：2007-07-26

  The present invention provides compounds of Formula I and salts, hydrates, solvates, complexes, and prodrugs thereof. The present invention further provides methods for synthesizing compounds of Formula I. The invention additionally provides pharmaceutical compositions comprising the compounds of Formula I and methods of using the pharmaceutical compositions of Formula I to treat and prevent disorders and diseases associated with the RyR receptors that regulate calcium channel functioning in cells.
• US6544987B2
  申请人：——

  公开号：US6544987B2

  公开（公告）日：2003-04-08